Dr. Eckhardt discusses Angiogenesis Inhibitors in mCRC

S. Gail Eckhardt, MD, professor and head of the Division of Medical Oncology at the University of Colorado Denver and Health Sciences Center, discusses the role of angiogenesis inhibitors in the treatment of metastatic colorectal cancer (mCRC), following the approval of aflibercept. For more resources and information regarding anticancer targeted therapies: http://targetedonc.com/